Developing a new gene therapy for treating muscle degeneration in older adults
Preclinical Development of a Novel Gene Therapeutic for Inclusion Body Myositis
This study is testing a new gene therapy called AVGN7 to help older adults with sporadic inclusion body myositis (IBM) by boosting muscle strength and function, with hopes of making life easier and more enjoyable for those living with this challenging condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aavogen, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project ID | NIH-10709907 on NIH RePORTER |
What this research studies
This research focuses on creating a novel gene therapy aimed at treating sporadic inclusion body myositis (IBM), a rare disease that primarily affects older adults and leads to progressive muscle degeneration. The approach involves using a gene therapeutic called AVGN7, which enhances muscle mass and function by suppressing certain signaling pathways that contribute to muscle wasting. The research includes preclinical studies to prepare for clinical trials, with the goal of providing a durable solution for patients suffering from this debilitating condition. If successful, this therapy could significantly improve the quality of life for those affected by IBM.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with sporadic inclusion body myositis.
Not a fit: Patients with muscle degeneration due to genetic mutations or other non-inflammatory causes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking treatment option that enhances muscle mass and function for patients with inclusion body myositis.
How similar studies have performed: Other research has shown promise in using gene therapy for muscle-related diseases, indicating potential success for this novel approach.
Where this research is happening
Rockville, United States
- Aavogen, INC. — Rockville, United States (Active)
Researchers
- Principal investigator: Rodgers, Buel — Aavogen, INC.
- Study coordinator: Rodgers, Buel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.